ヒトオルガノイド市場：臓器タイプ別、由来別、用途別、エンドユーザー別、地域別、機会、予測、2018年～2032年

世界のヒトオルガノイドの市場規模は、2025年～2032年の予測期間中に12.85%のCAGRで拡大し、2024年の12億3,000万米ドルから2032年には32億3,000万米ドルに成長すると予測されています。世界のヒトオルガノイド市場は、がんや神経疾患などの慢性疾患の有病率の上昇や、先進的な創薬・毒性モデルに対する需要の高まりにより、予測期間中に成長すると期待されています。

ヒトオルガノイドは、バイオテクノロジーとライフサイエンスにおける革新的なブレークスルーであり、幹細胞の進歩、革新的な薬物検出に対する需要の増加、慢性疾患の有病率の上昇により、ヒトオルガノイド市場は大きく成長する準備が整っています。ヒトの幹細胞や前駆細胞に由来するこれらの3D構造体は、基本的にヒトの臓器の構造や機能を再現したものであり、生物医学研究のための非常に現実的なプラットフォームを作り出し、動物モデルに代わる、より精密で倫理的な選択肢を提供します。個別化医療、疾病モデリング、再生療法は、世界中の製薬会社、大学、政府への投資によって急速に推進、開発されています。また、がん、神経変性疾患などの複雑な疾患の研究や従来の前臨床試験へのオルガノイド技術の導入も市場を支えています。ヒト・オルガノイド市場は、技術の進歩と精密医療への関心の高まりに支えられ、安定した成長が見込まれています。

当レポートでは、世界のヒトオルガノイド市場について調査し、市場の概要とともに、臓器タイプ別、由来別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のヒトオルガノイド市場の見通し、2018年～2032年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2024年
  • 臓器タイプ別
  • 由来別
  • 用途別
  • エンドユーザー別
  • 地域別

第5章 北米のヒトオルガノイド市場の見通し、2018年～2032年

第6章 欧州のヒトオルガノイド市場の見通し、2018年～2032年

第7章 アジア太平洋のオルガノイド市場の見通し、2018年～2032年

第8章 南米のヒトオルガノイド市場の見通し、2018年～2032年

第9章 中東・アフリカのヒトオルガノイド市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場参入企業トップ10の情勢
  • Thermo Fisher Scientific Inc.
  • Emulate, Inc.
  • Visikol, Inc.
  • Alveolix AG
  • Synthecon, Inc.
  • AxoSim, Inc.
  • 3Dnamics Inc.
  • Cellesce Ltd.
  • STEMCELL Technologies Inc.
  • Charles River Laboratories.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 3. Global Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 4. Global Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 5. Global Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 6. Global Human Organoids Market Share (%), By Region, 2018-2032F
• Figure 7. North America Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 9. North America Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 10. North America Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 11. North America Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 12. North America Human Organoids Market Share (%), By Country, 2018-2032F
• Figure 13. United States Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 15. United States Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 16. United States Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 17. United States Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 18. Canada Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 20. Canada Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 21. Canada Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 22. Canada Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 23. Mexico Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 25. Mexico Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 26. Mexico Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 27. Mexico Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 28. Europe Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 30. Europe Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 31. Europe Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 32. Europe Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 33. Europe Human Organoids Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 36. Germany Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 37. Germany Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 38. Germany Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 39. France Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 41. France Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 42. France Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 43. France Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 44. Italy Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 46. Italy Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 47. Italy Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 48. Italy Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 49. United Kingdom Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 51. United Kingdom Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 52. United Kingdom Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 53. United Kingdom Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 54. Russia Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 56. Russia Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 57. Russia Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 58. Russia Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 59. Netherlands Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 61. Netherlands Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 62. Netherlands Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 63. Netherlands Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 64. Spain Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 66. Spain Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 67. Spain Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 68. Spain Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 69. Turkey Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 71. Turkey Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 72. Turkey Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 73. Turkey Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 74. Poland Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 76. Poland Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 77. Poland Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 78. Poland Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 79. South America Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 81. South America Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 82. South America Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 83. South America Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 84. South America Human Organoids Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 87. Brazil Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 88. Brazil Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 89. Brazil Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 90. Argentina Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 92. Argentina Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 93. Argentina Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 94. Argentina Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 95. Asia-Pacific Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 97. Asia-Pacific Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 98. Asia-Pacific Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 99. Asia-Pacific Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 100. Asia-Pacific Human Organoids Market Share (%), By Country, 2018-2032F
• Figure 101. India Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 103. India Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 104. India Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 105. India Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 106. China Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 108. China Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 109. China Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 110. China Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 111. Japan Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 113. Japan Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 114. Japan Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 115. Japan Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 116. Australia Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 118. Australia Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 119. Australia Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 120. Australia Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 121. Vietnam Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 123. Vietnam Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 124. Vietnam Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 125. Vietnam Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 126. South Korea Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 128. South Korea Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 129. South Korea Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 130. South Korea Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 131. Indonesia Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 133. Indonesia Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 134. Indonesia Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 135. Indonesia Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 136. Philippines Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 138. Philippines Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 139. Philippines Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 140. Philippines Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 141. Middle East & Africa Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 143. Middle East & Africa Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 144. Middle East & Africa Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 145. Middle East & Africa Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 146. Middle East & Africa Human Organoids Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 149. Saudi Arabia Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 150. Saudi Arabia Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 151. Saudi Arabia Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 152. UAE Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 154. UAE Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 155. UAE Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 156. UAE Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 157. South Africa Human Organoids Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Human Organoids Market Share (%), By Organ Type, 2018-2032F
• Figure 159. South Africa Human Organoids Market Share (%), By Source, 2018-2032F
• Figure 160. South Africa Human Organoids Market Share (%), By Application, 2018-2032F
• Figure 161. South Africa Human Organoids Market Share (%), By End-user, 2018-2032F
• Figure 162. By Organ Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global human organoids market is projected to witness a CAGR of 12.85% during the forecast period 2025-2032, growing from USD 1.23 billion in 2024 to USD 3.23 billion in 2032. The global human organoids market is expected to thrive during the forecast period due to the increasing prevalence of chronic diseases such as cancer and neurological disorders and the rising demand for advanced drug discovery and toxicology models.

Human organoids are an innovative breakthrough in biotechnology and life sciences, with the market for human organoids prepared for significant growth due to the advances of stem cells, an increase in demand for innovative drug detection, and the growing prevalence of chronic diseases. These 3D structures, derived from the human stem or progenitor cells, are essentially replicas of human organs in terms of architecture and functionality, creating a highly realistic platform for biomedical research and offering more precise and ethical alternatives to animal models. Individualized medicine, illness modeling, and regenerative therapy are promoted and developed rapidly by investing in pharmaceutical companies, universities, and governments worldwide. The market is also supported by the introduction of organoid technology to study complex diseases such as cancer, neurodegenerative disorders, and conventional preclinical examinations. The human organoid market is expected to grow steadily, supported by technological advancements and growing interest in precision medicine. For instance, in November 2024, Axonis Therapeutics, Inc. used the International Space Station (ISS) National Lab to grow 3D brain organoids in microgravity, enabling successful testing of a reprogrammed viral vector for neurological gene therapy. This breakthrough advanced their therapeutic development and secured USD 115 million in funding for further research.

Increasing Prevalence of Chronic Diseases Boosts Market Growth

Increased incidences of chronic diseases represent a major growth driver in the human organoids market since such innovative 3D models provide unprecedented opportunities for understanding the complex mechanisms of diseases and developing targeted therapies. Cancer, diabetes, neurodegenerative diseases, and cardiovascular diseases are all gaining ground worldwide, creating a huge need for advanced research tools that can accurately recapitulate the functions of human organs. Human organoids represent a unique opportunity to model chronic disease progression in a controlled, human-friendly environment and test drug efficacy, thus identifying novel therapeutic targets. This is especially driven by the failure of traditional 2D cell culture and animal models to predict clinical outcomes. For instance, in June 2024, DefiniGEN Ltd. and Atelerix Ltd. successfully shipped stable in vitro liver models to a top United States pharma client. The models, combining induced pluripotent stem cells (iPSCs) derived hepatocytes and hydrogel preservation, enable efficient drug testing without the need for animal models, improving drug development and research processes.

Rising Demand for Advanced Models in Drug Discovery and Toxicology Drives Market Growth

Increasing demand for advanced drug discovery and toxicology models is a key growth driver for the global human organoids market because 3D models offer significant advantages over traditional 2D cell cultures and animal testing. Human organoids provide a more physiologically relevant platform for assessing drug efficacy, toxicity, and safety profiles, allowing pharmaceutical companies and research institutions to predict human responses better. Organoids made of cells that closely mimic the structure and complexity of human organs enable more accurate specification of potential drug candidates and long-term effects, thus increasing overall success in clinical trials. This propels market growth further, supported by advances in stem cell technology, investments in biotechnology, and the growing understanding of the limitations of traditional preclinical models.

For instance, in June 2023, Inventia Life Science Pty Ltd, a leader in advanced cell models, entered into a distribution agreement with Biotron Healthcare Pvt Ltd, granting Biotron sales rights for Inventia's RASTRUM platform in India. The RASTRUM platform, which enables the rapid creation of complex 3D cell cultures for disease modeling, drug discovery, and biomedical research, is designed for high-throughput applications. This partnership aims to enhance research capabilities in India, particularly in the pharmaceutical and academic sectors, by providing a simplified, automated solution to 3D bioprinting challenges.

Regenerative Medicine Segment to Dominate the Human Organoids Market

The regenerative medicine segment is projected to lead the global market for human organoids, led by the rising demand for new solutions in tissue repair and organ regeneration. Organoids are significant in advancing the prospects of regenerative therapies, especially for chronic diseases and organ failure, as they can replicate human organ functionality and structure. As the number of patients demanding personalized treatments surges, organoids create an important tool for simulating organ regeneration and forming patient-specific therapeutic strategies. Stem cell research and advancements in tissue engineering are also expanding the application of organoids in regenerative medicine through testing regenerative therapies and drug candidates much more effectively. The rising interest in reducing organ transplant dependency, along with the increasing capabilities of organoids to support tissue regeneration and repair, makes the regenerative medicine segment a promising growth driver in the market. For instance, in July 2024, Bioserve Biotechnologies (India) Private Ltd. launched advanced stem cell products from REPROCELL in India to advance scientific research, drug development, and regenerative medicine. The stem cell market, a rapidly growing sector, supports various industries involved in the research, manufacturing, and distribution of stem cell therapy products, driving innovation in therapeutic discovery.

North America Dominates the Human Organoids Market

North America is anticipated to be the dominating region in the human organoids market. Characterized by a strong research and development infrastructure, high governmental and private investments, and leading technological innovation. This region's key benefits are the presence of several giant pharmaceutical companies and academic centers engaged in the forefront of developing technologies for drug discovery, disease modeling, and personalized medicines. The presence of a favorable regulatory framework, as well as adequate funding for the field of regenerative medicine and stem cell research, boosts the adoption of human organoids in North America. Additionally, the growing demand for advanced, human-relevant models for preclinical drug testing, coupled with an increasing incidence of chronic diseases, propels the market growth. The FDA Modernization Act 2.0, signed in December 2022, permits the use of alternatives to animal testing, such as cell-based assays and computer models, for drug development. This shift aims to reduce costs, ethical concerns, and delays caused by animal model shortages, accelerating the drug approval process and fostering innovative testing methods.

Future Market Scenario (2025-2032F)

Developments in Stem Cell Technology: Technological progress in the sphere of stem cell research will gradually push the organoids ahead into more complex and better-fitting models for particular requirements.

Rise in Personalized Medication: The increasing tendency toward customized therapy, especially in cancer therapy and neurodegenerative conditions, increases the adoption of organoids in precision medicines.

Technological Innovation: Advances in 3D bioprinting, bioreactors, and scalable culture systems will enhance the functionality of organoids and make them more applicable in commercial settings.

Regulatory Support: Growing regulatory acceptance of organoid-based models for drug testing and disease research will support growth and adoption in the market.

Emerging Markets Growth: The increasing biotechnology investments and healthcare needs in regions such as Asia-Pacific and North America will lead to the rapid growth of the market in these regions.

Ethical Factors: The pressure for minimal animal testing combined with the ethical superiority of human-relevant models makes for the increased use of organoids in research and development.

Key Players Landscape and Outlook

The global human organoids market is segmented by organ type, including culture systems and bioreactors, and services, such as organoid-based research and drug testing. The fragmented services market contrasts with the type of market, dominated by key manufacturers. Recent developments include innovative launches, research center setups, and strategic mergers, driving growth in personalized medicine and regenerative therapies.

For instance, in May 2024, Crown Bioscience, Inc., signed a five-year collaboration agreement with the Shanghai Model Organisms Center (SMOC) to expand their immuno-oncology platforms and services globally. The agreement includes the supply of genetically engineered mouse models, cell line development, and custom model creation, offering uniform pricing, IP protection, and licensing rights across Crown's worldwide facilities.

For instance, in June 2023, AMSBIO Biotechnology (Europe) Limited launched MatriMix, a novel 3D culture substrate designed for advanced applications such as organoid formation and Induced Pluripotent Stem Cells (IPSCs) culture. This hydrogel contains fully defined components, including medical-grade collagens, laminin-511 E8 fragments, and hyaluronic acid, ensuring high lot-to-lot consistency and reproducibility. MatriMix addresses the limitations of current 3D substrates, providing superior performance in in-vivo animal PDX models and supporting cutting-edge biomedical research.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Human Organoids Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Organ Type
    • 4.2.1.1. Kidney
    • 4.2.1.2. Liver
    • 4.2.1.3. Brain
    • 4.2.1.4. Pancreas
    • 4.2.1.5. Heart
    • 4.2.1.6. Intestine
    • 4.2.1.7. Others
  • 4.2.2. By Source
    • 4.2.2.1. Embryonic Stem Cells (ESCs)
    • 4.2.2.2. Induced Pluripotent Stem Cells (IPSCs)
    • 4.2.2.3. Adults Stem Cells (ASCs)
  • 4.2.3. By Application
    • 4.2.3.1. Disease Modeling
    • 4.2.3.2. Drug Discovery and Toxicology
    • 4.2.3.3. Regenerative Medicine
    • 4.2.3.4. Cancer Research
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals and Diagnostic Laboratories
    • 4.2.4.2. Academic and Research Institute
    • 4.2.4.3. Pharmaceuticals and Biotechnology Company
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Organ Type
  • 4.3.2. By Source
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Human Organoids Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Organ Type
    • 5.2.1.1. Kidney
    • 5.2.1.2. Liver
    • 5.2.1.3. Brain
    • 5.2.1.4. Pancreas
    • 5.2.1.5. Heart
    • 5.2.1.6. Intestine
    • 5.2.1.7. Others
  • 5.2.2. By Source
    • 5.2.2.1. Embryonic Stem Cells (ESCs)
    • 5.2.2.2. Induced Pluripotent Stem Cells (IPSCs)
    • 5.2.2.3. Adults Stem Cells (ASCs)
  • 5.2.3. By Application
    • 5.2.3.1. Disease Modeling
    • 5.2.3.2. Drug Discovery and Toxicology
    • 5.2.3.3. Regenerative Medicine
    • 5.2.3.4. Cancer Research
    • 5.2.3.5. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Hospitals and Diagnostic Laboratories
    • 5.2.4.2. Academic and Research Institute
    • 5.2.4.3. Pharmaceuticals and Biotechnology Company
    • 5.2.4.4. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Human Organoids Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Organ Type
        • 5.3.1.2.1.1. Kidney
        • 5.3.1.2.1.2. Liver
        • 5.3.1.2.1.3. Brain
        • 5.3.1.2.1.4. Pancreas
        • 5.3.1.2.1.5. Heart
        • 5.3.1.2.1.6. Intestine
        • 5.3.1.2.1.7. Others
      • 5.3.1.2.2. By Source
        • 5.3.1.2.2.1. Embryonic Stem Cells (ESCs)
        • 5.3.1.2.2.2. Induced Pluripotent Stem Cells (IPSCs)
        • 5.3.1.2.2.3. Adults Stem Cells (ASCs)
      • 5.3.1.2.3. By Application
        • 5.3.1.2.3.1. Disease Modeling
        • 5.3.1.2.3.2. Drug Discovery and Toxicology
        • 5.3.1.2.3.3. Regenerative Medicine
        • 5.3.1.2.3.4. Cancer Research
        • 5.3.1.2.3.5. Others
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Hospitals and Diagnostic Laboratories
        • 5.3.1.2.4.2. Academic and Research Institute
        • 5.3.1.2.4.3. Pharmaceuticals and Biotechnology Company
        • 5.3.1.2.4.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Human Organoids Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Human Organoids Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Human Organoids Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Human Organoids Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals
• 17.2. Innovations

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Thermo Fisher Scientific Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Emulate, Inc.
  • 20.3.3. Visikol, Inc.
  • 20.3.4. Alveolix AG
  • 20.3.5. Synthecon, Inc.
  • 20.3.6. AxoSim, Inc.
  • 20.3.7. 3Dnamics Inc.
  • 20.3.8. Cellesce Ltd.
  • 20.3.9. STEMCELL Technologies Inc.
  • 20.3.10. Charles River Laboratories.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer